|
Immunovant Inc (NASDAQ: IMVT) |
|
Immunovant Inc
IMVT's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Immunovant Inc 's sales fell
in the third quarter of 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.05 %
Immunovant Inc net loss increased from $-51 millions, to $-111 millions in third quarter of 2024,
• More on IMVT's Growth
|
|
Immunovant Inc realized a net loss in trailing twelve months.
Immunovant Inc realized cash reduction of $ -2.15 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.79.
• More on IMVT's Valuation
|
|
|
|
|
Immunovant Inc realized net loss in trailing twelve months.
Immunovant Inc realized cash outflow of $ -2.15per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.79.
Immunovant Inc Price to Book Ratio is at 5.84 lower than Industry Avg. of 72794.86. and higher than S&P 500 Avg. of 0.01
• More on IMVT's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com